Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marina V. Mayevskaya"'
Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)
Autor:
Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 6, Pp 69-83 (2018)
Aim of investigation. Nowadays the question, whether pegylated interferon should be completely abandoned in the treatment of chronic hepatitis C (CHC) is still open. Beneficial interferon properties include: absence of mutagenic capacity for hepatiti
Externí odkaz:
https://doaj.org/article/14e4f35f52b640b1807d773161107b05
Autor:
V. T. Ivashkin, Marina V. Mayevskaya, Ch. S. Pavlov, I. N. Tikhonov, Ye. N. Shirokova, A. O. Buyeverov, O. M. Drapkina, Yu. O. Shulpekova, V. V. Tsukanov, S. N. Mammayev, I. V. Mayev, L. K. Palgova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 2, Pp 24-42 (2016)
Externí odkaz:
https://doaj.org/article/e3690daac3e54e938f94187b3f4a603b
Autor:
L K Palgova, Kirill M Starostin, Marina V Mayevskaya, Chavdar S Pavlov, Vladimir Ivashkin, Igor V. Maev, Aleksey A Samsonov
Publikováno v:
Turk J Gastroenterol
BACKGROUND: Essential phospholipids (EPL) are used as adjuvant treatment in people with fatty liver disease and other chronic liver diseases. A new formulation of EPL paste was developed to improve patient compliance. The study was aimed to assess th
Autor:
V. T. Ivashkin, Marina V. Mayevskaya, Ch. S. Pavlov, I. N. Tikhonov, Ye. N. Shirokova, A. O. Buyeverov, O. M. Drapkina, Yu. O. Shulpekova, V. V. Tsukanov, S. N. Mammayev, I. V. Mayev, L. K. Palgova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 2, Pp 24-42 (2018)